Physician profile
Munna Garg
NPI 1902895444
$4,313.83
in general payments reported to CMS, 2019-2025
35 companies · $500 in 2025
The $500 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $598 · 2021: $135 · 2022: $346 · 2023: $921 · 2024: $582 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $792.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $511.11 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $506.29 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $384.53 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $351.91 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Horizon Therapeutics Plc | $245.22 | 2021-2022 | |
| Pfizer INC. | $187.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $157.92 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Vertos Medical, INC. | $147.95 | 2023 | Mild Device Kit |
| Eisai INC. | $120.27 | 2020-2024 | |
| Exact Sciences Corporation | $79.46 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $79.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2019-2024 | Jardiance, Tradjenta |
| Abbvie INC. | $76.68 | 2022-2025 | |
| Amarin Pharma, INC. | $76.03 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.67 | 2024 | Veozah |
| Tris Pharma INC | $49.19 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $42.89 | 2025 | Gemtesa |
| Allergan, INC. | $42.80 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.81 | 2020 | |
| Globus Medical, INC. | $35.67 | 2025 | Senza |
| Axsome Therapeutics, INC. | $24.49 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $24.01 | 2023 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $22.75 | 2025 | Strensiq |
| Esperion Therapeutics, INC. | $22.19 | 2023 | Nexletol |
| Sanofi Pasteur INC. | $21.28 | 2023 | |
| Collegium Pharmaceutical, INC. | $19.96 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.82 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $18.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.74 | 2023 | Camzyos |
| Ironshore Pharmaceuticals INC. | $14.73 | 2019 | |
| Medtronic, INC. | $14.33 | 2021 | |
| Mylan Specialty L.P. | $13.61 | 2020 | |
| Shire North American Group INC | $12.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munna Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.